Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 284

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 284
---
 components of the Company’s
deferred tax assets are as follows:

| Deferred tax assets:                          |     | December 31, 
 2023         |        |   |     | 2022 |        |   |
|:----------------------------------------------|:----|:-------------|-------:|:--|:----|:-----|-------:|:--|
| Net operating loss carry forward              |     | $            | 40,064 |   |     | $    | 39,803 |   |
| Deferred tax asset before valuation allowance |     |              |  9,214 |   |     |      |  9,155 |   |
| Valuation allowance                           |     |              | (9,214 | ) |     |      | (9,155 | ) |
| Net deferred tax asset                        |     | $            |      - |   |     | $    |      - |   |

In assessing the realization of deferred
tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

The ultimate realization of the deferred
tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible
and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance as of
December 31, 2023 and 2022.

| e. | Effective tax expense (benefit): |

The components of loss before tax and
a reconciliation of the Company’s income tax expense to the Company’s theoretical statutory tax benefit is as follows:

|                                                                                                                  |     | Year Ended December 31, |  2023 |   |     |   |  2022 |   |
|:-----------------------------------------------------------------------------------------------------------------|:----|:------------------------|------:|:--|:----|:--|------:|:--|
| Loss before taxes on income                                                                                      |     | $                       | 4,132 |   |     | $ | 1,449 |   |
| Israeli statutory income tax rate                                                                                |     |                         |  23.0 | % |     |   |  23.0 | % |
| Theoretical statutory tax benefit                                                                                |     |                         |   950 |   |     |   |   333 |   |
| Revaluation of convertible notes                                                                                 |     |                         |  (464 | ) |     |   |   (